Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

Health Services Research & Development

Veterans Crisis Line Badge
Go to the ORD website
Go to the QUERI website

HSR&D Citation Abstract

Search | Search by Center | Search by Source | Keywords in Title

Rothman AL, Rosdahl JA, Hunter TG, Challa P, Muir KW. Treatment Outcomes Following Resident Performed Nonvalved (Baerveldt 350) Glaucoma Drainage Device Implantation. Journal of glaucoma. 2019 Nov 1; 28(11):958-964.
PubMed logo Search for Abstract from PubMed
(This link leaves the website of VA HSR&D.)

Abstract: PRECIS: When compared with outcomes by glaucoma specialists in several prospective studies, residents at the Durham Veterans Affairs Medical Center achieved comparable reductions in intraocular pressure (IOP) and failure rates during the year following Baerveldt drainage device implantation. PURPOSE: To review the outcomes of resident performed Baerveldt implantation through 1 year of postoperative management in a resident-run clinic. MATERIALS AND METHODS: The medical records of all veterans at the Durham Veterans Affairs Medical Center were searched to identify those with Baerveldt implantation by resident physicians from July 1, 2007 to June 30, 2017. Exclusion criteria include previous glaucoma tube or concurrent surgical intervention, including cataract extraction. All postoperative visits were reviewed and clinical data were collected. Failure was defined as 2 consecutive visits, starting at postoperative month (POM) 3, with IOP = 5?mm Hg, or with IOP > 21?mm Hg or < 20% IOP reduction from baseline, reoperation for glaucoma, or loss of light perception. RESULTS: A total of 48 eyes were included with mean (SD) IOP and number of medications: baseline, 23.1 (6.7)?mm Hg on 3.7 (1.0) medications; postoperative day 1, 20.5 (11.7)?mm Hg on no medications; postoperative week 1, 14.3 (6.9)?mm Hg and 1.9 (1.7) medications; POM1, 16.7 (6.4)?mm Hg and 2.2 (1.5) medications; POM3, 15.1 (5.2)?mm Hg and 2.1 (1.6) medications; POM6 12.8 (4.9)?mm Hg and 2.8 (1.3) medications; POM12, 13.0 (4.0)?mm Hg and 2.8 (1.4) medications. IOP decreased at all time intervals (P < 0.01) but postoperative day 1 (P = 0.15) while medication burden was reduced at every visit (P < 0.01). Through 12 months, 8 patients (17%) failed with a time to failure of 9.2 (0.3) months. No patients underwent additional glaucoma surgical interventions or lost light perception. CONCLUSIONS: Residents can safely and efficaciously perform Baerveldt implantation, providing reassurance regarding the autonomy afforded residents in the operating room and clinic.

Questions about the HSR&D website? Email the Web Team.

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.